Expression Analysis of Serum MicroRNA-34a and MicroRNA-183 in Hepatocellular Carcinoma

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2018 Sep 27

PMID 30256056

Citations 14

Authors

Dipu Bharali

Hakim B Jebur

Debabrat Baishya

Suresh Kumar

Manash P Sarma

Mirza Masroor

Juheb Akhter

Syed A Husain

Premashis Kar

Affiliations

Soon will be listed here.

Abstract

Background/objective: HCC is a multistep process starting from chronic hepatitis that progress through cirrhosis to HCC. MicroRNA expression level was found to be deregulated in HCC. To find out whether the expression level of miR-34a and miR-183 was deregulated in HCC compared to controls without HCC. Methods: Real time quantitative PCR was done to find out the miRNA expression level in terms of Ct value followed by statistical analysis. Results: Over-expression of miR-183 and under-expression of miR-34a in HCC was detected. All changes in expression level of miR-34a and miR-183 were found to be due to HCC compared to controls without HCC. So both miR-34a and miR-183 were suitable to differentiate HCC from Cirrhosis and chronic hepatitis with an efficient diagnostic power of sensitivity, specificity and expression level. But they might not have any role in patients’ survival. Conclusion: miR- 34a and miR-183 might be considered as potential markers of HCC screening molecule in addition to other approved panel of marker. Our study warrants further expression level study.

Citing Articles

Predictive three-biomarker panel in peripheral blood mononuclear cells for detecting hepatocellular carcinoma.

Fayazzadeh S, Ghorbaninejad M, Rabbani A, Zahiri J, Meyfour A Sci Rep. 2024; 14(1):7527.

PMID: 38553531 PMC: 10980807. DOI: 10.1038/s41598-024-58158-9.

Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma.

You J, Xia H, Huang Z, He R, Zhao X, Chen J Front Oncol. 2023; 13:1204715.

PMID: 37546394 PMC: 10400719. DOI: 10.3389/fonc.2023.1204715.

Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease.

Ragab H, Ezzat W, Mahmoud Hassan E, Maksoud N, Afify M, Abd El-Maksoud M J Genet Eng Biotechnol. 2023; 21(1):13.

PMID: 36757530 PMC: 9911573. DOI: 10.1186/s43141-023-00467-z.

During HCV DAA Therapy Plasma Mip1B, IP10, and miRNA Profile Are Distinctly Associated with Subsequent Diagnosis of Hepatocellular Carcinoma: A Pilot Study.

Damjanovska S, Alao H, Zebrowski E, Kowal C, Kostadinova L, Davitkov P Biology (Basel). 2022; 11(9).

PMID: 36138741 PMC: 9495750. DOI: 10.3390/biology11091262.

The current landscape of microRNAs (miRNAs) in bacterial pneumonia: opportunities and challenges.

Zhang F, Zhou Y, Ding J Cell Mol Biol Lett. 2022; 27(1):70.

PMID: 35986232 PMC: 9392286. DOI: 10.1186/s11658-022-00368-y.

References

Lee J, Wong C, Ng I . Hepatitis B virus-associated multistep hepatocarcinogenesis: a stepwise increase in allelic alterations. Cancer Res. 2008; 68(14):5988-96. DOI: 10.1158/0008-5472.CAN-08-0905. View

Leung W, He M, Chan A, Law P, Wong N . Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Lett. 2015; 362(1):97-105. DOI: 10.1016/j.canlet.2015.03.023. View

Krol J, Loedige I, Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010; 11(9):597-610. DOI: 10.1038/nrg2843. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Qiao D, Yang J, Lei X, Mi G, Li S, Li K . Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features. Eur Rev Med Pharmacol Sci. 2017; 21(4):742-747. View

Breving K, Esquela-Kerscher A . The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol. 2009; 42(8):1316-29. DOI: 10.1016/j.biocel.2009.09.016. View

Tian Y, Shen Q, Jiang Q, Wang Y, Li K, Xue H . Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma. Minerva Med. 2016; 108(2):108-113. DOI: 10.23736/S0026-4806.16.04616-4. View

Jiang J, Gusev Y, Aderca I, Mettler T, Nagorney D, Brackett D . Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008; 14(2):419-27. PMC: 2755230. DOI: 10.1158/1078-0432.CCR-07-0523. View

Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R . Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009; 49(4):1098-112. DOI: 10.1002/hep.22749. View

10.

Midorikawa Y, Yamamoto S, Tsuji S, Kamimura N, Ishikawa S, Igarashi H . Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology. 2008; 49(2):513-22. DOI: 10.1002/hep.22698. View

11.

Goeppert B, Schmezer P, Dutruel C, Oakes C, Renner M, Breinig M . Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology. 2010; 52(6):2023-33. DOI: 10.1002/hep.23939. View

12.

Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108(12):5003-8. PMC: 3064324. DOI: 10.1073/pnas.1019055108. View

13.

Runyon B . Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013; 57(4):1651-3. DOI: 10.1002/hep.26359. View

14.

Liu A, Yao T, Wang W, Wong K, Lee N, Fan S . Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012; 2(2):e000825. PMC: 3308260. DOI: 10.1136/bmjopen-2012-000825. View

15.

He L, He X, Lowe S, Hannon G . microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer. 2007; 7(11):819-22. PMC: 4053212. DOI: 10.1038/nrc2232. View

16.

Chang T, Wentzel E, Kent O, Ramachandran K, Mullendore M, Lee K . Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26(5):745-52. PMC: 1939978. DOI: 10.1016/j.molcel.2007.05.010. View

17.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

18.

Liang Z, Gao Y, Shi W, Zhai D, Li S, Jing L . Expression and significance of microRNA-183 in hepatocellular carcinoma. ScientificWorldJournal. 2013; 2013:381874. PMC: 3810064. DOI: 10.1155/2013/381874. View

19.

Yang Z, Wang L . Regulation of microRNA expression and function by nuclear receptor signaling. Cell Biosci. 2011; 1(1):31. PMC: 3192659. DOI: 10.1186/2045-3701-1-31. View

20.

Um T, Kim H, Oh B, Kim M, Kim K, Jung G . Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol. 2010; 54(5):939-47. DOI: 10.1016/j.jhep.2010.08.021. View